We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Drug Targets Early Instigator of Alzheimer's Disease

News   Aug 15, 2019 | Original story from Arizona State University

 
Drug Targets Early Instigator of Alzheimer's Disease

DYR219 is a powerful new drug developed by Travis Dunckley and his colleagues and described in the new study. Its strength lies in the fact that it can target both of the leading pathologies associated with Alzheimer's disease--plaques, (caused by the protein amyloid beta) and tangles, (caused by the tau protein). Credit: Graphic by Shireen Dooling

 
 
 

RELATED ARTICLES

Have a Cuppa While You Mull It Over

News

Regular tea drinkers have better organised brain regions – and this is associated with healthy cognitive function – compared to non-tea drinkers.

READ MORE

Perfecting a Method To Predict the Potential of New Drugs

News

Researchers are perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

READ MORE

B Cells May Be More Important in Immunotherapy Than Previously Thought

News

Researchers have found evidence that B cells might play an important role in immunotherapy for melanoma. Currently, immunotherapy is primarily focused on T cells, but the results suggest that B cells could also provide an interesting research avenue.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE